Comparison of the seizure drug levetiracetam with controlled release carbamazepine in new focal seizure patients
Phase 4
Completed
- Conditions
- Health Condition 1: G400- Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onsetHealth Condition 2: G402- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizuresHealth Condition 3: G401- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
- Registration Number
- CTRI/2019/05/018990
- Lead Sponsor
- Institutional sponsored
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 74
Inclusion Criteria
The study will include all the newly diagnosed consenting adult patients of focal seizures without any other co-morbidities
Exclusion Criteria
Patients not willing to give written informed consent.
Pregnant females.
Patients already on treatment with study drugs.
Patients of seizures others than focal seizures.
Patients of head trauma within past one month.
Patients with known contraindication or refractoriness to study drugs.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Minimal adverse drug reactions and seizure freedomTimepoint: At 1 month, 3 months and 6 months
- Secondary Outcome Measures
Name Time Method PharmacoeconomicsTimepoint: At 6 months;Quality of life outcomeTimepoint: Before initiating treatment and at 6 months